September 8, 2025.
MELBOURNE, Australia and SAN FRANCISCO — September 8, 2025 — Leads & Copy — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced it secured A$20.0 million in a capital raise through binding commitments for fully paid ordinary shares. The funds came from international and Australian professional investors.
The company will use the proceeds to fund non-clinical studies, manufacturing activities, clinical and regulatory activities for future development of ATH434 in MSA, and general working capital.
According to David Stamler, M.D., CEO of Alterity, the company elected to execute this placement due to inbound interest from a high-quality international healthcare-focused fund that anchored the transaction. He added that the additional funding allows them to continue advancing their clinical and regulatory strategy for ATH434 with the US FDA and other agencies, while strengthening their institutional register and balance sheet to best position the company for pursuing strategic partnerships.
MST Financial Services Pty Ltd (MST) acted as sole manager of the offering.
Ana Luiza Harrop (we-aualteritytherapeutics@we-worldwide.com, +61 452 510 255)
Remy Bernarda (remy.bernarda@iradvisory.com, +1 (415) 203-6386)
Source: Alterity Therapeutics Limited
